- Three months ago, I wrote an article for SA on Xbrane. I predicted a strong share price growth by the Phase 3 readout. Xbrane doubled.
- Biovica is a similar case. It should double in the next three months. For the same reasons as Xbrane did.
- Cancer diagnostics is a strongly evolving field. Biovica’s novel cancer test can detect breast cancer progress cheaper and much faster than current methods.
- Its unprecedented 30 clinical trials in the prominent US and European hospitals minimize the risk of FDA failure. Biovica expects FDA approval and US launch by the Q3 end.
- Share prices of pharma companies tend to move strongly before a major catalyst. Biovica should be a perfect example of this.